[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Philippe Klee, MD-PhD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":5},"100568534",false,"NCT06682481","Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function","Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function: From Mice to Children","Inclusion Criteria:\n\n* Children aged 12 to 16 years\n* Obesity. Defined as a body-mass index above the 97th percentile.\n* Ability to give informed consent as documented by signature\n\nExclusion Criteria:\n\n* Patients with diabetes mellitus and positive autoantibodies against islets, insulin, islet antigen 2, glutamic acid decarboxylase or Zinc transporter 8.\n* Patients with known liver disease (other than NAFLD)\n* Patients treated with an oral antidiabetic drug, glucagon-like peptide-1 analogues or insulin at the time of or less than 2 weeks prior to inclusion.\n* Patients treated with a drug known to affect liver function","ALL","12 Years","16 Years",{"count":19,"type":20},50,"ESTIMATED","OBSERVATIONAL","The investigators will measure blood levels of 1,5-anhydroglucitol in obese children with or without type 2 diabetes and correlate them with parameters related to functional beta-cell mass and glucose metabolism. The values will be compared to those obtained in healthy volunteers. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in children with obesity with or without type 2 diabetes.",[24,25],"Obesity, Childhood","Type 2 Diabetes Mellitus in Obese","RECRUITING","2026-05-14",{"date":29,"type":30},"2026-05-18","ACTUAL",{"date":32,"type":30},"2024-11-22",{"date":34,"type":20},"2028-12-31",{"name":36,"class":37},"Philippe Klee, MD-PhD","OTHER",""]